In the TIME trial, the timing of stem cell delivery in patients with ST-segment elevation myocardial infarction (STEMI) was investigated. Patients with STEMI who were reperfused with primary percutaneous coronary intervention and stenting and had a left ventricular ejection fraction ≤45% received treatment with bone marrow mononuclear cells (n = 65) or placebo (n = 30). Irrespective of whether the cells were delivered 3 days or 7 days after the infarction, the injection of bone marrow mononuclear cells did not improve outcomes at 1 year relative to placebo treatment.
References
Traverse, J. H. et al. One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction. JAMA 10.1001/jama.2013.282674
Rights and permissions
About this article
Cite this article
BMCs are not effective to treat patients with STEMI. Nat Rev Cardiol 11, 5 (2014). https://doi.org/10.1038/nrcardio.2013.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.193